A series of setbacks almost caused the demise of PARP inhibitors, but four companies are now beginning pivotal trials of these agents in breast and ovarian cancer.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. PARP inhibitors bounce back. Nat Rev Drug Discov 12, 725–727 (2013). https://doi.org/10.1038/nrd4147
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4147
This article is cited by
-
Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue
Nature Communications (2016)
-
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Scientific Reports (2015)
-
European regulators approve first PARP inhibitor
Nature Reviews Drug Discovery (2014)
-
PARP inhibitors and IR join forces to strike glioblastoma-initiating cells
Cell Death & Differentiation (2014)
-
Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?
Protein & Cell (2014)
